This is the third lawsuit to be filed in the wake of Yellowstone revising its bison management plan last year.

Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with MASH, a common and progressive chronic liver ...